

# The effect of clindamycin and lincomycin on angiogenic activity of human blood mononuclear cells

DOROTA M. RADOMSKA-LEŚNIEWSKA<sup>1</sup>, EWA SKOPIŃSKA-RÓŻEWSKA<sup>2</sup>, JACEK MALEJCZYK<sup>1</sup>

<sup>1</sup>Department of Histology and Embryology, Center for Biostructure Research, Medical University of Warsaw, Poland

<sup>2</sup>Pathology Department, Center for Biostructure Research, Medical University of Warsaw, Poland

## Abstract

*Clindamycin and lincomycin have a similar mode of antibacterial action, similar antibacterial spectra and they are used frequently in clinical practice. Irrespective of their anti-microbial properties they are suggested to modulate immune function. The aim of our study was to estimate the effect of these antibiotics on neovascular reaction induced in mice skin by mononuclear cells (MNC) collected from the blood of 8 healthy volunteers. Mononuclear cells were injected intradermally into anaesthetized Balb/c inbred mice. Clindamycin, lincomycin or PBS (control) were administered subcutaneously into the mice over 3 days at doses of 3, 15 and 75 mg/kg of the body mass. The number of newly formed blood vessels was counted in dissection microscope 72 h after cells injection. Lincomycin did not change the results of angiogenesis tests comparing to the control. On the contrary, clindamycin administration resulted in strong stimulation of angiogenic response at all used doses. Monocytes and CD8+ cells inhibited angiostimulatory effect of clindamycin administration.*

**Key words:** *clindamycin, lincomycin, angiogenesis, immune system modifiers, mononuclear cells.*

*(Centr Eur J Immunol 2010; 35 (4): 217-222)*

## Introduction

Antibiotics are used in clinical practice very frequently. One should realize, however, that antibiotic therapy may deeply influence human organism changing its homeostasis. It may concern many important processes including host inflammatory and immune response [1].

Clindamycin and lincomycin belong to lincosamides with chemical structure consisting of amino acid and sugar moieties. Their antimicrobial activity is based on protein synthesis inhibition by binding to the 50S ribosomal subunit [2]. Lincomycin occurs naturally, while clindamycin is a semi-synthetic chlorinated derivative of lincomycin and exhibits improved antibacterial activity. Staphylococci and streptococci as well as *Bacteroides fragilis* and some other anaerobes are sensitive to lincosamides treatment. Clindamycin therapy is effective in dental infection, toxic shock syndrome and directly block the M protein production that leads to the severe inflammatory response. It has high oral absorption and significant tissue penetration including bone [3].

Formation of new blood vessels from preexisting ones, defined as angiogenesis, is essential for a variety of physiological processes like embryogenesis, reproductive functions and wound repair. The process of angiogenesis is regulated by various angiogenic and angiostatic/angiostatic factors. Increased angiogenesis plays a critical role in pathogenesis of various diseases including cancer, diabetic retinopathy, rheumatoid arthritis and other chronic inflammatory disorders. On the other hand, a decreased new blood vessels formation underlies poor wounds and fractures repair, coronary heart disease and other ischemic conditions [4].

Angiogenesis is regarded as a part of cell immunity and that is why it can be also a good model for immune response examination (immunological angiogenesis). Lowered angiogenic activity of MNCs collected from the blood of elderly people, patients suffering from candidosis, patients with coronary heart disease and patients with scleroderma was reported using leukocyte-

Correspondence: Dorota M. Radomska-Leśniewska, Department of Histology and Embryology, Center for Biostructure Research, Medical University of Warsaw, ul. Chałubińskiego 5, 02-004 Warsaw, Poland, phone +48 22 629 56 75, fax +48 22 629 52 82, e-mail: mradomska@ib.amwaw.edu.pl

induced mice cutaneous angiogenesis test, LIA [5-7]. Increased angiogenic activity of MNCs isolated from the blood and synovial fluid of rheumatoid arthritis patients and from the blood of patients with psoriasis or epidermodysplasia verruciformis were reported as well [8-10]. Several natural drugs and herbal extracts behaved as stimulators of immunological angiogenesis induced by MNCs; among them Tolpa peat preparation (TPP), stimulating angiogenic activity of T cells and monocytes, water extracts of *Hypericum perforatum* L and *Melissa officinalis* L; *Echinacea purpurea* extracts, ether fraction of poplar leaves water extract and isolated from this fraction phenolic acids: caffeic, gallic, salicylic, ferulic and gentisic. Chlorogenic acid behaved as immunomodulator. It increased angiogenic activity of MNCs collected from healthy donors, and decreased abnormally high angiogenic activity of MNCs collected from the blood of rheumatoid arthritis patients. The same was observed for TPP [8, 11-13].

The results provide evidence that antibiotics may affect angiogenesis. Previous study of our group revealed a different influence of cephalosporin antibiotics using LIA test. The results depend on the kind of cells used for angiogenesis induction as well as on the kind of antibiotic applied and its doses [14, 15]. Some antibiotics (ceftazidime, ceftriaxone and cefsulodin) suppressed, while cefuroxime and ceftazidime enhanced, neovascularization of healthy people's MNC. Cefoperazone did not exert any effect on angiogenic response of healthy people's MNC, although it increased angiogenic activity of bronchialveolar lavage cells obtained from sarcoidosis patients. Lung cancer cells' as well as ovarian cancer cells' angiogenic activity was diminished after cefoperazone and cefuroxime administration, indicating that this kind of anti-infective therapy could be beneficial for cancer patients.

The information concerning the effect of lincosamides on angiogenic activity of mononuclear leukocytes is scarce. Also, information on the effect of antibiotics from this group on immunity is limited [16-24]. Clindamycin and lincomycin are often used in bone and joint surgery, where correct healing process is extremely important. Knowledge about the effect of selected antibiotic on an important part of repair process – angiogenesis – should be obligatory. Therefore, the aim of our work was to evaluate the effect of two antibiotics from lincosamides group – clindamycin and lincomycin – on neovascular reaction induced in mice by intradermal grafting of healthy volunteers blood mononuclear cells.

## Materials and methods

All experiments were performed with mononuclear cells (MNC) obtained from peripheral blood of 8 healthy volunteers from Institute of Tuberculosis and Lung Diseases which signed Informed Consens.

Following antibiotics were tested:

- Dalacin (Clindamycin phosphate), Upjohn, Belgium,
- Lincomycine HCL, Upjohn, Belgium.

## Isolation of mononuclear leukocytes

Mononuclear leukocytes (MNC) were isolated from blood by centrifugation on Ficoll/Uropline gradient, according to Boyum [25]. The viability of isolated cells was determined by trypan blue exclusion and was always higher than 98%.

## Monocyte elimination

Mononuclear cells suspension was mixed with carbonyl iron (15 mg/10<sup>7</sup> cells) and incubated for 1 h, at 37°C in plastic bottles. Non adherent cells were poured into the tubes, and phagocytic and lymphoid cells were separated using a magnet. The lymphoid cells (0-2% peroxidase positive, < 3% BMA 0310 positive) were washed twice and resuspended in PBS – FCS or Parker medium.

## CD8 positive cells elimination

Monocyte – depleted cell suspensions (2 × 10<sup>7</sup> cell/ml) were incubated for 30 min at 4°C with 5 µg/ml monoclonal antibody (BMA 081). Then the cells were washed twice and resuspended in PBS medium supplemented with 2% inactivated FCS. Cell suspensions were placed on plastic Petri dishes precoated with affinity purified rabbit anti-mouse IgG for 30 min at room temperature and then 30 min in 37°C, and washed in PBS. Cell suspensions enriched with CD4 positive cells contained less than 1% CD8 positive cells, as estimated by APAAP method.

## Angiogenesis test

Angiogenesis test was performed according to Sidky and Auerbach [26] with some modifications [27]. All experiments were performed on inbred 6-8 week old Balb/c mice, from the Polish Academy of Sciences' breeding colony. Various fractions of human MNC were injected intradermally in 4-6 places (5 × 10<sup>5</sup> per inoculum) into anesthetized mice. Afterwards, antibiotics were administered subcutaneously into the mice (3 mice in one group) for 3 consecutive days at daily dose of 3, 15 and 75 mg/kg of the body mass. Mice from the control group were injected with PBS. Each experiment was repeated at least 2 times. After 72 h mice were sacrificed and newly formed blood vessels were counted in dissection microscope (magnification 6 ×) on the inner skin surface.

Experiments were approved by Local Ethical Committee.

### Statistical analysis

Angiogenic activity was calculated as a number of newly formed blood vessels and presented as an index (I) counted from the formula:  $I = a/b$ , (a: newly formed blood vessels in tested group; b: mean number of newly formed blood vessels in the control group)

All data are shown as a mean  $\pm$  SEM. The differences between the groups were evaluated by two-way ANOVA followed by Bonferroni post-test. The differences were considered significant at  $p$ -value  $< 0.05$ . Evaluation of the results of experiments with cell fractions was done by one-way ANOVA followed by Tukey's post-test (GraphPadPrism software).

### Results

Results were shown in Table 1, Table 2, Fig. 1 and Fig. 2.

The effect of lincosamides on neovascular response depended on the type of antibiotic and was dose-independent. Lincomycin (each dose), did not alter neovascular response comparing to the control group of mice. Strong stimulation of angiogenic response was observed for each used dose of clindamycin. In recipients of monocyte-depleted MNC statistically higher stimulatory effect of clindamycin (15 mg/kg) was observed, than in recipients of full suspension of MNC. The highest stimulation of neovascular response was observed in monocyte and CD8+ cells depleted cell suspension.

### Discussion

Regardless of the dose used in our experiments, clindamycin produced a strong stimulatory effect on new blood vessels formation, while lincomycin did not exert any effect in cutaneous angiogenesis test. We also observed monocyte- and CD8+ cells- dependent inhibition of angiostimulatory response of the full MNC suspensions after clindamycin administration.


There aren't many publications concerning immunomodulatory activity of lincomycin. This antibiotic in subminimal doses increased the susceptibility of *S. aureus* on cytotoxic activity of human MNC [16]. Lincomycin administered before and 6h after surgical ovariectomy prevented development of an infection [17]. Lincomycin used at the dose of 17 mg/kg/day was found to be effective in protecting mice from endogenous septic shock in  $\beta$ -glucan-indomethacin model, by modulating gut microbial flora [18]. Furthermore, proinflammatory cytokines production (IL-6, TNF- $\alpha$ ) was decreased by lincomycin in *in vitro* spleen cell cultures.

Clindamycin was described to have stimulatory effect on immune system.


Ammurio *et al.* [19] have shown stimulation of phagocytic activity of mouse macrophages *in vivo* at the dose of 40 mg/kg and lack of the effect at 15 mg/kg after 1 week of treatment. Stimulation of phagocytic activity by this antibiotic was also reported by other author in *ex vivo* and *in vivo* experiments [20]. Moreover, clindamycin did not exert any effect on protein synthesis nor chemotaxis [21]. Roszkowski *et al.* [22] has found that LPS or Concanavalin A induced lymphocyte proliferation as well as humoral immunity was not influenced by clindamycin.

In the present work we obtained evidence of beneficial stimulatory effect of clindamycin on the ability of human peripheral blood mononuclear leukocytes to release proangiogenic factors. Experiments with cell fractions revealed that stimulatory effect is significantly more pronounced after removing monocytes and CD8+ lymphocytes from the injected cell suspension. It suggests that cell target for clindamycin is CD4+ lymphocyte. The same cell target was observed in experiments with two angiostimulatory herbal remedies- Tołpa Peat Preparation (TPP) and *Rhodiola rosea* hydro-alcoholic extract [8, 28, 29].

We previously reported, that the highest angiogenic activity was expressed by T cells forming rosettes with SRBC and bearing both the receptor for the Fc portion of



**Fig. 1.** The effect of clindamycin and lincomycin on angiogenic activity of MNC



**Fig. 2.** The effect of clindamycin on various fractions of MNC in angiogenesis test

**Table 1.** Two-way analysis of variance of experiments with clindamycin and lincomycin (full MNC)

<b>Two-way ANOVA</b>				
Source of Variation	% of total variation	<i>p</i> -value		
Interaction	0.27	0.9332		
Drug	37.90	< 0.0001		
Dose	0.03	0.9542		
Source of Variation	<i>p</i> -value summary	significant?		
Interaction	NS	No		
Drug	***	Yes		
Dose	NS	No		
Source of Variation	Df	sum-of-squares	mean square	F
Interaction	4	0.05562	0.01390	0.2090
Drug	2	7.673	3.836	57.66
Dose	2	0.006233	0.003116	0.04684
Residual	188	12.51	0.06653	
Number of missing values	64			
<b>Bonferroni posttest</b>				
control vs. clindamycin				
dose	control	clindamycin	difference	95% CI of diff.
3 mg/kg	1.000	1.420	0.4200	0.2068 to 0.6332
15 mg/kg	1.000	1.400	0.4000	0.1825 to 0.6175
75 mg/kg	1.000	1.440	0.4400	0.2297 to 0.6503
dose	difference	t	<i>p</i> -value	summary
3 mg/kg	0.4200	5.252	< 0.001	***
15 mg/kg	0.4000	4.904	< 0.001	***
75 mg/kg	0.4400	5.579	< 0.001	***
control vs. lincomycin				
dose	control	lincomycin	difference	95% CI of diff.
3 mg/kg	1,000	1,020	0,02000	-0,1978 to 0,2378
15 mg/kg	1,000	1,010	0,01000	-0,1899 to 0,2099
75 mg/kg	1,000	0,9600	-0,04000	-0,2525 to 0,1725
dose	difference	t	<i>p</i> -value	summary
3 mg/kg	0.02000	0.2449	> 0.05	NS
15 mg/kg	0.01000	0.1334	> 0.05	NS
75 mg/kg	-0.04000	0.5019	> 0.05	NS

**Table 2.** One-way analysis of variance (experiments with cells fractions and clindamycin)

<b>One-way ANOVA</b>				
P-value	< 0.0001			
P-value summary	***			
Are means signif. different? ( $p < 0.05$ )	Yes			
Number of groups	3			
F	13.7			
R square	0.3246			
<b>Bartlett's test for equal variances</b>				
Bartlett's statistic (corrected)	0.8113			
P-value	0.6666			
P-value summary	NS			
Do the variances differ signif. ( $p < 0.05$ )	No			
<b>Tukey's Multiple Comparison Test</b>				
	mean difference	q	significant? $p < 0,05?$	summary
MNC vs. MNC – monocytes	-0.1	4.731	Yes	**
MNC vs. MNC – monocytes and CD8+ cells	-0.18	7.268	Yes	***
MNC – monocytes vs. MNC - monocytes and CD8+ cells	-0.08	3.396	No	NS

IgG and a CD4 surface antigen [30, 31]. Later we described two subpopulations of highly angiogenic human T lymphocytes: first, CD4+ FcG+ with CD2 receptors sensitive to theophylline, and second, CD4+ FcG– with CD2 receptors resistant to theophylline [32, 33].

## Conclusion

Results of our work indicate that clindamycin may be used during infections of patients with low angiogenesis level (for example ischemic heart disease), for improving new vessels formation during prolonged repair and healing processes in infected patients. It may also be used for antibiotic treatment to prevent infectious complications in joint replacement [34] and for the treatment of infected pseudoarthrosis.

This work was partly performed in the Institute of Tuberculosis and Lung Diseases, Płocka 26, Warsaw, Poland.

## References:

1. Tauber SC, Nau R (2008): Immunomodulatory properties of antibiotics. *Curr Mol Pharmacol* 1: 68-79.
2. Spížek J, Novotná J, Režanka T (2004): Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance, and applications. *Adv Appl Microbiol* 56: 121-154.
3. Brook I, Lewis M, Sandor G, et al. (2006): Clindamycin in dentistry: More than just effective prophylaxis for endocarditis? *Oral Surg, Oral Pathol Oral Med, Oral Radiol Endodontology* 101: 698-700.
4. Skopińska-Różewska E, Skopiński P (2001): Modulation of angiogenesis-new field of clinical immunology. *Terapia* 3 (2): 3-6.
5. Polakowski IJ, Skopińska-Różewska E, Wróblewski T, Pawińska M (1987): Angiogenesis induced by human peripheral blood lymphocytes: studies on the effect of donors' age and sex on reaction intensity. *Pol Tyg Lek XLII*: 595-596.
6. Kamiński MJ, Majewski S, Jabłońska S, Pawińska M (1984): Lowered angiogenic capability of peripheral blood lymphocytes in progressive systemic sclerosis(scleroderma). *J Invest Dermatol* 82: 239-243.
7. Makowiecki K, Sommer E, Pawińska M, et al. (1994): Angiogenesis in ischemic heart disease. *Kardiol Pol* 41: 287-292.
8. Skopińska-Różewska E, Polakowski I, Żukowska M, et al. (1993): The effect of Tołpa peat preparation (TPP) on human mononuclear leukocytes induced angiogenesis. *Herba Pol* 39: 41-48.
9. Majewski S, Kamiński M, Jabłońska S, et al. (1985): Angiogenic capability of peripheral blood MNC in psoriasis. *Arch Dermatol* 12: 1018-1021.
10. Majewski S, Skopińska-Różewska E, Jabłońska S, et al. (1986): Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis. *J Am Acad Dermatol* 15: 966-973.
11. Glinkowska G, Bałan BJ, Sommer E, et al. (1997): The effect of phenolic compounds of poplar leaves extract on cutaneous angiogenesis reaction induced in mice by human MNC. *Acta Pol Pharm* 54: 151-154.
12. Mierzwińska-Nastalska E, Demkow U, Siwicki AK, et al. (2005): The effect of Echinacea purpurea extract Echinapur on the angiogenic and chemokinetic activity of human leukocytes. *Pol J Environ Studies* 14 (supl II): 639-642.



13. Skopińska-Różewska E, Sommer E, Bałan BJ, et al. (2010): The in vivo effect of dry hydro-alcoholic extract of *Echinacea purpurea* on angiogenic activity of human blood mononuclear cells. *Centr Eur J Immunol* 35; in press.
14. Radomska-Leśniewska D, Skopińska-Różewska E, Jankowska-Steifer E (2010): The effect of selected cephalosporins on angiogenic activity of human blood mononuclear cells. *Centr Eur J Immunol* 35: 14-19.
15. Rogala E, Chorostowska-Wynimko J, Radomska D, et al. (1998): Modulatory effect of cephalosporins on cutaneous angiogenic reaction induced in mice by human non-malignant and malignant cells. Therapeutic Implication and Mechanism of Angiogenesis. Novel therapeutic development. IBC's Fourth Annual Conference. 23-24 April 1998, Boston, USA.
16. Cialdella JJ, Varra JJ, Marsal VP (1986): Susceptibility of bacteria to serum lysis or phagocytosis following growth in subinhibitory of lincosaminide or spectinomycin related antibiotics. *Jantibiot*, Tokyo 39: 978-984.
17. Rizzo A, Pantaleo M, Mutinati M, et al. (2009): Effect of antibiotics on biochemical parameters, leukocytes and reactive oxygen species (ROS) in bitches after ovariectomy. *Immunopharmacol Immunotoxicol* 31: 682-687.
18. Sachico N, Miura NN, Adachi Y, Ohno N (2007): Lincomycin protects mice from septic shock in  $\beta$ -glucan-indomethacin model. *Biol Pharm Bull* 30: 2312-2316.
19. Ammurio C, Lewden S, Nicolas R, et al. (1990): Effect of treatment with clindamycin, erythromycin, rifamycin or gentamycin on the ingestion capacity of peritoneal macrophages in mice. *Pathol Biol Paris* 38: 13-18.
20. Villa ML, Rappocido G, Piacca P, Clerici E (1986): The interference of antibiotics with antigen-specific antibody responses in man. *Int. J Immunopharmacol* 8, 805-809.
21. Forsgren A, Schmelig D (1977): Effect of antibiotic on chemotaxis of human leucocytes. *Antimicrob Agents Chemother* 11: 580-584.
22. Roszkowski W, Ko HL, Jeliaszewicz J, Pulwerer G (1985): Antibiotics and immunomodulation. Effects of cefotaxime, ampicillin, mezlocillin, piperacillin and clindamycin. *Med Microbiol Immunol* 173: 279-289.
23. Wijaya A, Wulansari R, Ano H, Makimura S (2001): Effects of clindamycin therapy on phagocytic and oxidative activity profiles of spleen mononuclear cells in *Babesia rohdahni*-infected mice. *J Vet Med Sci* 63: 563-566.
24. Wittmann S, Arlt M, Rothe G, Frohlich D (2004): Differential effects of clindamycin on neutrophils of healthy donors and septic patients. *Int Immunopharmacol* 4: 929-937.
25. Boyum A (1968): Isolation of mononuclear cells by one centrifugation and sedimentation at 1 g. *Scand J Clin Lab Invest* 97: 77-89.
26. Sidky YA and Auerbach R (1975): Lymphocyte-induced angiogenesis: a quantitative and sensitive assay for the graft-versus-host reaction. *J Exp Med* 141: 1084-1100.
27. Skopińska-Różewska E, Sommer E, Demkow U, et al. (1997): Screening of angiogenesis inhibitors by modified TIA test in lung cancer. *Annales Acad Med Bialostocensis* 42 (Suppl 1): 287-296.
28. Furmanowa M, Olędzka H, Michalska M, et al. *Rhodiola rosea* L (Roseroot): In vitro regeneration and the biological activity of roots. In: *Biotechnology In Agriculture and Forestry*. Vol 33. Medicinal and aromatic plants VIII (Ed. by YPS Bajaj) Springer-Verlag Berlin Heidelberg 1995; pp 412-426.
29. Furmanowa M, Skopińska-Różewska E, Rogala E, Hartwich M (1998): *Rhodiola rosea* in vitro culture – phytochemical analysis and antioxidant action. *Acta Societ Botanic Poloniae* 67: 69-73.
30. Kamiński MJ, Nowaczyk M, Skopińska-Różewska E, et al. (1981): Human peripheral blood T – lymphocyte subpopulations isolated on the basis of their affinity to sheep red blood cells differ in angiogenesis-inducing capability. *Clin Exp Immunol* 46: 327-331.
31. Polakowski IJ, Żukowska M, Włodarska B, et al. (1988): A contribution to studies on the mechanism of lymphocyte-induced angiogenesis: human peripheral blood mononuclear leukocytes with highest angiogenic activity. *Folia Biol (Praha)* 34: 350-355.
32. Skopińska-Różewska E, Ettenger RB, Plaeger-Marshall S, et al. (1988): Surface antigens of theophylline-resistant and theophylline-sensitive human E rosette – forming T lymphocytes. *Folia Biol* 34: 58-62.
33. Żukowska M, Skopińska-Różewska E, Mierzińska-Nastalska E (2001): Role of the theophylline resistant and theophylline sensitive T lymphocytes in angiogenesis. *Terapia* 3(2) 16-17.
34. Jahoda D, Nyc O, Pokorný D, et al. (2006): Antibiotic treatment for prevention of infectious complications in joint replacement. *Acta Chir Orthop Traumatol Cech* 73: 108-114.